What's happening with ASX uranium stocks amid Sprott doubling investment to $200M

ASX investors have witnessed share price gains of up to 30% for the largest uranium stocks this week.

| More on:
A miner stands in front of an excavator at a mine site.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

ASX uranium stocks are enjoying an incredible week of share price growth amid news that Canadian investment fund Sprott will buy $200 million of physical uranium, double the original investment announced earlier this week.

Sprott's purchase, along with regulatory changes in the US to bring more nuclear reactors online, sparked the rally in ASX uranium stocks this week.

Since Monday, Boss Energy Ltd (ASX: BOE) shares have soared 26.1% to $4.63 apiece at the time of writing.

Boss Energy shares gathered further momentum yesterday when the company announced it had met its first-year production guidance.

Earlier today, the Boss Energy share price hit a 52-week high of $4.75. The stock has since lost steam and is down 0.64% now.

Similarly, the Deep Yellow Ltd (ASX: DYL) share price has rocketed 31.3% this week to $1.70 currently.

Deep Yellow shares also reached a 52-week high of $1.76 in morning trade. They have since reversed course into the red, down 1.45%.

The Paladin Energy Ltd (ASX: PDN) share price is up 17.8% this week to $7.42 at the time of writing.

The market's largest ASX 200 uranium stock hit a four-month high of $7.56 this morning but has since slipped 2.05%.

Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is up 0.014%.

What's put a rocket under ASX uranium stocks this week?

ASX uranium stocks initially lifted on news that the Sprott Physical Uranium Trust would buy $100 million of uranium.

The plan was to fund this purchase via a capital raise with underwriter Canaccord Genuity Corp.

According to Newswire, strong investor demand has prompted Sprott to expand the capital raise and double its purchase to $200 million.

Now, Canaccord will buy 11,600,000 units of the uranium trust, up from 5,800,000, for US$17.25 apiece.

The total gross proceeds will be US$200,100,000. Canaccord plans to close the offer tomorrow.

The uranium price leapt 9.25% to a six-month high of US$76.20 per pound earlier in the week.

Trading Economics analysts said uranium acquisitions by Sprott commonly trigger rallies in the uranium price.

This is due to how thin uranium derivatives trade.

Sprott is a global asset manager focused on precious metals and critical materials investments.

The purchase comes amid the US moving to grow domestic nuclear power.

Last year, the US allocated up to $2.7 billion in funding to support uranium supply and enrichment capacity.

Last month, US President Trump signed four executive orders aimed at reinvigorating the local nuclear energy industry.  

Trading Economics analysts say global uranium demand has also been supported by power-hungry AI data centres.

This is why news that Amazon will invest an extra $20 billion in Australian AI centres also buoyed ASX uranium stocks this week.

Meanwhile, the world's largest uranium producer, Kazakhstan's NAC Kazatomprom JSC, has advised it will achieve a mid-point production of 14 million pounds in 2025.

Trading Economics analysts said this is nearly 20% below the production guidance Kazatomprom provided in late 2023.

Lower-than-expected production from global producers of any commodity tends to strengthen commodity prices because it limits supply.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon. The Motley Fool Australia has recommended Amazon. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Energy Shares

Female miner uses mobile phone at mine site
Energy Shares

Here are the latest growth forecasts for the Pilbara Minerals share price

Can investors charge up their returns with this ASX lithium share?

Read more »

An oil worker in front of a pumpjack using a tablet.
Energy Shares

Top 5 ASX 200 energy shares of FY25 amid a challenging year for sector

The energy sector was the weakest of the 11 market sectors in FY25.

Read more »

An oil worker on a tablet with an oil rig in the background.
Energy Shares

Buying Woodside shares? Here's the latest oil price forecast from Goldman Sachs

Here’s what Goldman Sachs is forecasting for the oil price in the year ahead.

Read more »

Natural gas plant engineer using a laptop.
Energy Shares

Santos share price pushes higher amid big Asian news

ASX investors are bidding up Santos shares on Friday.

Read more »

a man and his small son crouch in a green field under a beautiful sunset sky looking at renewable, wind generators for energy production.
Energy Shares

Non-oil energy investments are on the rise: Here are 2 to consider

Australian investors are turning their attention to non-oil energy stocks poised for growth.

Read more »

Oil rig worker standing with a clipboard.
Energy Shares

How much upside does Macquarie tip for Woodside shares?

With shares up 23% since April, here’s Macquarie’s 12-month forecast for the Woodside share price.

Read more »

A male oil and gas mechanic wearing a white hardhat walks along a steel platform above a series of gas pipes in a gas plant.
Energy Shares

Should I buy Santos shares today amid the ongoing $30 billion takeover offer?

With the $30 billion Santos takeover offer not yet finalised, should you buy shares right now?

Read more »

Workers inspecting a gas pipeline.
Broker Notes

What's Macquarie's price target for Origin Energy shares?

Could Origin be primed for a turnaround?

Read more »